New insights into the prevention of staphylococcal infections and toxic shock syndrome

References

• Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg. Infect. Dis.13(12), 1840–1846 (2007).
   PubMed Web of Science ®Google Scholar
• Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992–2003. Clin. Infect. Dis.42(3), 389–391 (2006).
   PubMed Web of Science ®Google Scholar
• King MD, Humphrey BJ, Wang YF, Kourbatova EV, Ray SM, Blumberg HM. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med.144(5), 309–317 (2006).
   PubMed Web of Science ®Google Scholar
• Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol.26(2), 175–183 (2005).
   PubMed Web of Science ®Google Scholar
• Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect. Control Hosp. Epidemiol.26(2), 166–174 (2005).
   PubMed Web of Science ®Google Scholar
• Klevens RM, Morrison MA, Nadle J et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA298(15), 1763–1771 (2007).
   PubMed Web of Science ®Google Scholar
• Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis.46(Suppl. 5), S344–S349 (2008).
   PubMed Web of Science ®Google Scholar
• Naimi TS, LeDell KH, Como-Sabetti K et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA290(22), 2976–2984 (2003).
   PubMed Web of Science ®Google Scholar
• Gorwitz RJ, Kruszon-Moran D, McAllister SK et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001–2004. J. Infect. Dis.197(9), 1226–1234 (2008).
   PubMed Web of Science ®Google Scholar
• Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med.355(7), 666–674 (2006).
   PubMed Web of Science ®Google Scholar
• Saiman L, O’Keefe M, Graham PL 3rd et al. Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women. Clin. Infect. Dis.37(10), 1313–1319 (2003).
   PubMed Web of Science ®Google Scholar
• Seybold U, Kourbatova EV, Johnson JG et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis.42(5), 647–656 (2006).
   PubMed Web of Science ®Google Scholar
• Limbago B, Fosheim GE, Schoonover V et al. Characterization of methicillin-resistant Staphylococcus aureus isolates collected in 2005 and 2006 from patients with invasive disease: a population-based analysis. J. Clin. Microbiol.47(5), 1344–1351 (2009).
   PubMed Web of Science ®Google Scholar
• Fey PD, Said-Salim B, Rupp ME et al. Comparative molecular analysis of community- or hospital-acquired methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.47(1), 196–203 (2003).
   PubMed Web of Science ®Google Scholar
• Bubeck Wardenburg J, Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med.205(2), 287–294 (2008).
   Google Scholar
• Brosnahan AJ, Mantz MJ, Squier CA, Peterson ML, Schlievert PM. Cytolysins augment superantigen penetration of stratified mucosa. J. Immunol.182(4), 2364–2373 (2009).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J. Infect. Dis.195(2), 202–211 (2007).
   PubMed Web of Science ®Google Scholar
• O’Riordan K, Lee JC. Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev.17(1), 218–234 (2004).
   PubMed Web of Science ®Google Scholar
• Song Y, Liu CI, Lin FY et al. Inhibition of staphyloxanthin virulence factor biosynthesis in Staphylococcus aureus: in vitro, in vivo, and crystallographic results. J. Med. Chem.52(13), 3869–3880 (2009).
   PubMed Web of Science ®Google Scholar
• Foster TJ. Immune evasion by staphylococci. Nat. Rev. Microbiol.3(12), 948–958 (2005).
   PubMed Web of Science ®Google Scholar
• Becker K, Friedrich AW, Lubritz G, Weilert M, Peters G, Von Eiff C. Prevalence of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains of Staphylococcus aureus isolated from blood and nasal specimens. J. Clin. Microbiol.41(4), 1434–1439 (2003).
   PubMed Web of Science ®Google Scholar
• Schlievert PM, Case LC, Strandberg KL, Tripp TJ, Lin YC, Peterson ML. Vaginal Staphylococcus aureus superantigen profile shift from 1980 and 1981 to 2003, 2004, and 2005. J. Clin. Microbiol.45(8), 2704–2707 (2007).
   Google Scholar
• Bernal A, Proft T, Fraser JD, Posnett DN. Superantigens in human disease. J. Clin. Immunol.19(3), 149–157 (1999).
   Google Scholar
• McCormick JK, Yarwood JM, Schlievert PM. Toxic shock syndrome and bacterial superantigens: an update. Annu. Rev. Microbiol.55, 77–104 (2001).
   PubMed Web of Science ®Google Scholar
• Andrews MM, Parent EM, Barry M, Parsonnet J. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. Clin. Infect. Dis.32(10), 1470–1479 (2001).
   Google Scholar
• Hajjeh RA, Reingold A, Weil A, Shutt K, Schuchat A, Perkins BA. Toxic shock syndrome in the United States: surveillance update, 1979 1996. Emerg. Infect. Dis.5(6), 807–810 (1999).
   PubMed Web of Science ®Google Scholar
• Schlievert PM, Tripp TJ, Peterson ML. Reemergence of staphylococcal toxic shock syndrome in Minneapolis–St. Paul, Minnesota, during the 2000–2003 surveillance period. J. Clin. Microbiol.42(6), 2875–2876 (2004).
   PubMed Web of Science ®Google Scholar
• Descloux E, Perpoint T, Ferry T et al. One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases. Eur. J. Clin. Microbiol. Infect. Dis.27(1), 37–43 (2008).
   Google Scholar
• Yarwood JM, Leung DY, Schlievert PM. Evidence for the involvement of bacterial superantigens in psoriasis, atopic dermatitis, and Kawasaki syndrome. FEMS Microbiol. Lett.192(1), 1–7 (2000).
   Google Scholar
• Li LB, Goleva E, Hall CF, Ou LS, Leung DY. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK–ERK) pathway. J. Allergy Clin. Immunol.114(5), 1059–1069 (2004).
   PubMed Web of Science ®Google Scholar
• Li LB, Leung DY, Hall CF, Goleva E. Divergent expression and function of glucocorticoid receptor β in human monocytes and T cells. J. Leukoc. Biol.79(4), 818–827 (2006).
   PubMed Web of Science ®Google Scholar
• Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch. Dis. Child.72(4), 308–311 (1995).
   PubMed Web of Science ®Google Scholar
• Leung DY, Meissner HC, Fulton DR, Murray DL, Kotzin BL, Schlievert PM. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet342(8884), 1385–1388 (1993).
   PubMed Web of Science ®Google Scholar
• Leung DY, Travers JB, Giorno R et al. Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis. J. Clin. Invest.96(5), 2106–2112 (1995).
   PubMed Web of Science ®Google Scholar
• Ou LS, Goleva E, Hall C, Leung DY. T regulatory cells in atopic dermatitis and subversion of their activity by superantigens. J. Allergy Clin. Immunol.113(4), 756–763 (2004).
   PubMed Web of Science ®Google Scholar
• Bunikowski R, Mielke ME, Skarabis H et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J. Allergy Clin. Immunol.105(4), 814–819 (2000).
   PubMed Web of Science ®Google Scholar
• Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J. Allergy Clin. Immunol.107(4), 607–614 (2001).
   PubMed Web of Science ®Google Scholar
• Semic-Jusufagic A, Bachert C, Gevaert P et al.Staphylococcus aureus sensitization and allergic disease in early childhood: population-based birth cohort study. J. Allergy Clin. Immunol.119(4), 930–936 (2007).
   PubMed Web of Science ®Google Scholar
• Lee PK, Vercellotti GM, Deringer JR, Schlievert PM. Effects of staphylococcal toxic shock syndrome toxin 1 on aortic endothelial cells. J. Infect. Dis.164(4), 711–719 (1991).
   Google Scholar
• Peterson ML, Ault K, Kremer MJ et al. The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin 1. Infect. Immun.73(4), 2164–2174 (2005).
   PubMed Web of Science ®Google Scholar
• Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin. Microbiol. Rev.13(1), 16–34 (2000).
   PubMed Web of Science ®Google Scholar
• Schlievert PM, Osterholm MT, Kelly JA, Nishimura RD. Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic shock syndrome. Ann. Intern. Med.96(6 Pt 2), 937–940 (1982).
   PubMed Web of Science ®Google Scholar
• O’Reilly M, Kreiswirth B, Foster TJ. Cryptic α-toxin gene in toxic shock syndrome and septicaemia strains of Staphylococcus aureus. Mol. Microbiol.4(11), 1947–1955 (1990).
   Google Scholar
• Menestrina G, Dalla Serra M, Comai M et al. Ion channels and bacterial infection: the case of β-barrel pore-forming protein toxins of Staphylococcus aureus. FEBS Lett.552(1), 54–60 (2003).
   Google Scholar
• Huseby M, Shi K, Brown CK et al. Structure and biological activities of β toxin from Staphylococcus aureus. J. Bacteriol.189(23), 8719–8726 (2007).
   PubMed Web of Science ®Google Scholar
• Rogolsky M. Nonenteric toxins of Staphylococcus aureus. Microbiol. Rev.43(3), 320–360 (1979).
   PubMedGoogle Scholar
• Tajima A, Iwase T, Shinji H, Seki K, Mizunoe Y. Inhibition of endothelial interleukin-8 production and neutrophil transmigration by Staphylococcus aureus β-hemolysin. Infect. Immun.77(1), 327–334 (2009).
   Google Scholar
• Huseby MJ, Kruse AC, Digre J et al. β toxin catalyzes formation of nucleoprotein matrix in staphylococcal biofilms. Proc. Natl Acad. Sci. USA107(32), 14407–14412 (2010).
   PubMed Web of Science ®Google Scholar
• Kaneko J, Kamio Y. Bacterial two-component and hetero-heptameric pore-forming cytolytic toxins: structures, pore-forming mechanism, and organization of the genes. Biosci. Biotechnol. Biochem.68(5), 981–1003 (2004).
   PubMed Web of Science ®Google Scholar
• Siqueira JA, Speeg-Schatz C, Freitas FI, Sahel J, Monteil H, Prevost G. Channel-forming leucotoxins from Staphylococcus aureus cause severe inflammatory reactions in a rabbit eye model. J. Med. Microbiol.46(6), 486–494 (1997).
   PubMed Web of Science ®Google Scholar
• Gravet A, Colin DA, Keller D, Girardot R, Monteil H, Prevost G. Characterization of a novel structural member, LukE–LukD, of the bi-component staphylococcal leucotoxins family. FEBS Lett.436(2), 202–208 (1998).
   PubMed Web of Science ®Google Scholar
• Lina G, Piemont Y, Godail-Gamot F et al. Involvement of Panton–Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis.29(5), 1128–1132 (1999).
   PubMed Web of Science ®Google Scholar
• Labandeira-Rey M, Couzon F, Boisset S et al.Staphylococcus aureus Panton–Valentine leukocidin causes necrotizing pneumonia. Science315(5815), 1130–1133 (2007).
   PubMed Web of Science ®Google Scholar
• Voyich JM, Otto M, Mathema B et al. Is Panton–Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis.194(12), 1761–1770 (2006).
   PubMed Web of Science ®Google Scholar
• Wang R, Braughton KR, Kretschmer D et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat. Med.13(12), 1510–1514 (2007).
   PubMed Web of Science ®Google Scholar
• Amagai M, Matsuyoshi N, Wang ZH, Andl C, Stanley JR. Toxin in bullous impetigo and staphylococcal scalded-skin syndrome targets desmoglein 1. Nat. Med.6(11), 1275–1277 (2000).
   PubMed Web of Science ®Google Scholar
• Rooijakkers SH, Ruyken M, Roos A et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol.6(9), 920–927 (2005).
   PubMed Web of Science ®Google Scholar
• Harraghy N, Hussain M, Haggar A et al. The adhesive and immunomodulating properties of the multifunctional Staphylococcus aureus protein Eap. Microbiology149(Pt 10), 2701–2707 (2003).
   PubMed Web of Science ®Google Scholar
• Fraser JD, Proft T. The bacterial superantigen and superantigen-like proteins. Immunol. Rev.225, 226–243 (2008).
   PubMed Web of Science ®Google Scholar
• Chen LF, Chopra T, Kaye KS. Pathogens resistant to antibacterial agents. Infect. Dis. Clin. North Am.23(4), 817–845, vii (2009).
   PubMed Web of Science ®Google Scholar
• Doss SA, Tillotson GS, Amyes SG. Effect of sub-inhibitory concentrations of antibiotics on the virulence of Staphylococcus aureus. J. Appl. Bacteriol.75(2), 123–128 (1993).
   Google Scholar
• Nailor MD, Sobel JD. Antibiotics for Gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect. Dis. Clin. North Am.23(4), 965–982, ix (2009).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis.49(3), 325–327 (2009).
   PubMed Web of Science ®Google Scholar
• Gilbert DN MR, Eliopoulous GM, Sande MA. The Sanford Guide to Antimicrobial Therapy 2006. Antimicrobial Therapy Inc., VA, USA (2006).
   Google Scholar
• Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome – associated exotoxin production. J. Infect. Dis.149(3), 471 (1984).
   PubMed Web of Science ®Google Scholar
• Ohlsen K, Ziebuhr W, Koller KP, Hell W, Wichelhaus TA, Hacker J. Effects of subinhibitory concentrations of antibiotics on α-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother.42(11), 2817–2823 (1998).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Wallace RJ, Hamilton SM, Bryant AE. Successful treatment of staphylococcal toxic shock syndrome with linezolid: a case report and in vitro evaluation of the production of toxic shock syndrome toxin type 1 in the presence of antibiotics. Clin. Infect. Dis.42, 729–730 (2006).
   PubMed Web of Science ®Google Scholar
• Rempe S, Hayden JM, Robbins RA, Hoyt JC. Tetracyclines and pulmonary inflammation. Endocr. Metab. Immune Disord. Drug Targets7(4), 232–236 (2007).
   PubMedGoogle Scholar
• Hoyt JC, Robbins RA. Macrolide antibiotics and pulmonary inflammation. FEMS Microbiol. Lett.205(1), 1–7 (2001).
   PubMed Web of Science ®Google Scholar
• Krakauer T, Buckley M. Doxycycline is anti-inflammatory and inhibits staphylococcal exotoxin-induced cytokines and chemokines. Antimicrob. Agents Chemother.47(11), 3630–3633 (2003).
   PubMedGoogle Scholar
• Norrby-Teglund A, Kaul R, Low DE et al. Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J. Immunol.156(8), 3057–3064 (1996).
   PubMed Web of Science ®Google Scholar
• Darenberg J, Ihendyane N, Sjolin J et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin. Infect. Dis.37(3), 333–340 (2003).
   PubMed Web of Science ®Google Scholar
• Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA267(24), 3315–3316 (1992).
   PubMed Web of Science ®Google Scholar
• Kaul R, McGeer A, Norrby-Teglund A et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome – a comparative observational study. The Canadian Streptococcal Study Group. Clin. Infect. Dis.28(4), 800–807 (1999).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis.41(10), 1373–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit. Care Med.35(12), 2686–2692 (2007).
   PubMed Web of Science ®Google Scholar
• Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) – beyond immunodeficiencies and neurology. Clin. Exp. Immunol.158(Suppl. 1), 23–33 (2009).
   PubMed Web of Science ®Google Scholar
• Ruzin A, Novick RP. Equivalence of lauric acid and glycerol monolaurate as inhibitors of signal transduction in Staphylococcus aureus. J. Bacteriol.182(9), 2668–2671 (2000).
   PubMed Web of Science ®Google Scholar
• Projan SJ, Brown-Skrobot S, Schlievert PM, Vandenesch F, Novick RP. Glycerol monolaurate inhibits the production of β-lactamase, toxic shock toxin-1, and other staphylococcal exoproteins by interfering with signal transduction. J. Bacteriol.176(14), 4204–4209 (1994).
   PubMed Web of Science ®Google Scholar
• Schlievert PM, Deringer JR, Kim MH, Projan SJ, Novick RP. Effect of glycerol monolaurate on bacterial growth and toxin production. Antimicrob. Agents Chemother.36(3), 626–631 (1992).
   PubMed Web of Science ®Google Scholar
• Peterson ML, Schlievert PM. Glycerol monolaurate inhibits the effects of Gram-positive select agents on eukaryotic cells. Biochemistry45(7), 2387–2397 (2006).
   PubMed Web of Science ®Google Scholar
• Schlievert PM, Strandberg KL, Brosnahan AJ et al. Glycerol monolaurate does not alter rhesus macaque (Macaca mulatta) vaginal lactobacilli and is safe for chronic use. Antimicrob. Agents Chemother.52(12), 4448–4454 (2008).
   Google Scholar
• McNamara PJ, Syverson RE, Milligan-Myhre K et al. Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1. Antimicrob. Agents Chemother.53(5), 1898–1906 (2009).
   Google Scholar
• Brissette JL, Cabacungan EA, Pieringer RA. Studies on the antibacterial activity of dodecylglycerol. Its limited metabolism and inhibition of glycerolipid and lipoteichoic acid biosynthesis in Streptococcus mutans BHT. J. Biol. Chem.261(14), 6338–6345 (1986).
   PubMed Web of Science ®Google Scholar
• Lin YC, Schlievert PM, Anderson MJ et al. Glycerol monolaurate and dodecylglycerol effects on Staphylococcus aureus and toxic shock syndrome toxin-1 in vitro and in vivo. PLoS ONE4(10), e7499 (2009).
   Google Scholar
• Schlievert PM, Nemeth KA, Davis CC, Peterson ML, Jones BE. Staphylococcus aureus exotoxins are present in vivo in tampons. Clin. Vaccine Immunol.17(5), 722–727).
   Google Scholar
• Schlievert PM, Case LC, Nemeth KA et al. α and β chains of hemoglobin inhibit production of Staphylococcus aureus exotoxins. Biochemistry46(50), 14349–14358 (2007).
   Google Scholar
• Buonpane RA, Churchill HR, Moza B et al. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat. Med.13(6), 725–729 (2007).
   PubMedGoogle Scholar
• Buonpane RA, Moza B, Sundberg EJ, Kranz DM. Characterization of T cell receptors engineered for high affinity against toxic shock syndrome toxin-1. J. Mol. Biol.353(2), 308–321 (2005).
   PubMed Web of Science ®Google Scholar
• Yang X, Buonpane RA, Moza B et al. Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats. J. Infect. Dis.198(3), 344–348 (2008).
   Google Scholar
• Shinefield H, Black S, Fattom A et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N. Engl. J. Med.346(7), 491–496 (2002).
   PubMed Web of Science ®Google Scholar
• Nanra JS, Timofeyeva Y, Buitrago SM et al. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine27(25–26), 3276–3280 (2009).
   PubMed Web of Science ®Google Scholar
• Tuchscherr LP, Buzzola FR, Alvarez LP, Lee JC, Sordelli DO. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice. Infect. Immun.76(12), 5738–5744 (2008).
   PubMed Web of Science ®Google Scholar
• Kuklin NA, Clark DJ, Secore S et al. A novel Staphylococcus aureus vaccine: iron surface determinant B induces rapid antibody responses in rhesus macaques and specific increased survival in a murine S. aureus sepsis model. Infect. Immun.74(4), 2215–2223 (2006).
   PubMed Web of Science ®Google Scholar
• Weisman LE, Thackray HM, Garcia-Prats JA et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrob. Agents Chemother.53(7), 2879–2886 (2009).
   PubMed Web of Science ®Google Scholar
• Brown EL, Dumitrescu O, Thomas D et al. The Panton–Valentine leukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300. Clin. Microbiol. Infect.15(2), 156–164 (2009).
   Web of Science ®Google Scholar
• Bubeck Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. Panton–Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis.198(8), 1166–1170 (2008).
   PubMedGoogle Scholar
• Lucero CA, Hageman J, Zell ER et al. Evaluating the potential public health impact of a Staphylococcus aureus vaccine through use of population-based surveillance for invasive methicillin-resistant S. aureus disease in the United States. Vaccine27(37), 5061–5068 (2009).
   PubMed Web of Science ®Google Scholar
• Wilke GA, Bubeck Wardenburg J. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus α-hemolysin-mediated cellular injury. Proc. Natl Acad. Sci. USA107(30), 13473–13478 (2010).
   PubMed Web of Science ®Google Scholar
• O’Brien GJ, Riddell G, Elborn JS, Ennis M, Skibinski G. Staphylococcus aureus enterotoxins induce IL-8 secretion by human nasal epithelial cells. Respir. Res.7, 115 (2006).
   PubMed Web of Science ®Google Scholar
• Peterson ML, Ault K, Kremer MJ et al. The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin 1. Infect. Immun.73(4), 2164–2174 (2005).
   PubMed Web of Science ®Google Scholar
• Musch MW, Petrof EO, Kojima K, Ren H, McKay DM, Chang EB. Bacterial superantigen-treated intestinal epithelial cells upregulate heat shock proteins 25 and 72 and are resistant to oxidant cytotoxicity. Infect. Immun.72(6), 3187–3194 (2004).
   Google Scholar
• Aubert V, Schneeberger D, Sauty A et al. Induction of tumor necrosis factor a and interleukin-8 gene expression in bronchial epithelial cells by toxic shock syndrome toxin 1. Infect. Immun.68(1), 120–124 (2000).
   Google Scholar
• Strandberg KL, Peterson ML, Schaefers MM et al. Reduction in Staphylococcus aureus growth and exotoxin production and in vaginal interleukin 8 levels due to glycerol monolaurate in tampons. Clin. Infect. Dis.49(11), 1711–1717 (2009).
   Google Scholar
• Ragle BE, Bubeck Wardenburg J. Anti-α-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect. Immun.77(7), 2712–2718 (2009).
   PubMed Web of Science ®Google Scholar
• Schaffer AC, Lee JC. Staphylococcal vaccines and immunotherapies. Infect. Dis. Clin. North Am.23(1), 153–171 (2009).
   PubMed Web of Science ®Google Scholar